Who are CureXcell's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tnkase, Floseal hemostatic matrix, Traditional Cryoprecipitate, Bleomycin + Fibrovein, rtPA, Tenecteplase or Alteplase.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/curexcell.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CureXcell — Competitive Intelligence Brief

CureXcell (CureXcell) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombolytic. Area: Cardiovascular.

phase 3 Thrombolytic Fibrin Cardiovascular Biologic Live · refreshed every 30 min

Target snapshot

CureXcell (CureXcell) — Macrocure Ltd.. CureXcell is a recombinant human thrombolytic enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CureXcell TARGET	CureXcell	Macrocure Ltd.	phase 3	Thrombolytic	Fibrin
Tnkase	TENECTEPLASE	Roche	marketed		fibrin	2000-01-01
Floseal hemostatic matrix	Floseal hemostatic matrix	Chang Gung Memorial Hospital	marketed	Hemostatic agent	Thrombin-mediated fibrin formation
Traditional Cryoprecipitate	Traditional Cryoprecipitate	Weill Medical College of Cornell University	marketed	Blood product; clotting factor concentrate	Fibrinogen, Factor VIII, von Willebrand factor, Fibronectin, Factor XIII
Bleomycin + Fibrovein	Bleomycin + Fibrovein	Oslo University Hospital	marketed	Chemotherapy agent with hemostatic adjuvant	DNA (bleomycin); fibrin polymerization (fibrovein)
rtPA	rtPA	Hui-Sheng Chen	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Plasminogen; fibrin
Tenecteplase or Alteplase	Tenecteplase or Alteplase	Insel Gruppe AG, University Hospital Bern	marketed	Tissue plasminogen activator (tPA); fibrinolytic agent	Plasminogen; fibrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombolytic class)

Macrocure Ltd. · 1 drug in this class
Tasly Biopharmaceuticals Co., Ltd. · 1 drug in this class
The George Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CureXcell — Competitive Intelligence Brief. https://druglandscape.com/ci/curexcell. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab